Samsung Biologics

Global biopharmaceutical CDMO leader based in South Korea

Healthtech & BiotechIncheon, South KoreaEast AsiaAdvantage marketLatest Mar 12, 2026

Add to Watchlist Website

Monitoring Status

Signals (30d)3

Most active typePartnership

Primary channelHealthtech & Biotech

vs. prior 30 days

Rising

Signals (30d)

Most Active Type

Partnership

Primary Theme

Biologics CDMO

Latest Update

Mar 12, 2026

Why this company matters

Samsung Biologics is the world's largest contract development and manufacturing organization (CDMO) for biologics, playing a critical role in global pharmaceutical supply chains.

Key domain relevance: Biologics CDMO, Biosimilars, Cell & Gene Therapy
Active monitoring with 3 signals in the last 30 days across 5 tracked sources.

Channel Context

Healthtech & Biotech

Samsung Biologics is a key company within the Healthtech & Biotech channel.Its official updates regularly contribute to how users track developments in this space, including strategic moves, partnerships, and technology shifts.

3 signals tracked to date in this channel.

View channel

Market Context

South KoreaGlobal

This company operates in one of SigFact's strongest advantage markets, where official updates often surface first in local language and can remain under-covered in English-language media.

Monitoring this company through SigFact helps close the language-barrier signal gap that affects most English-first platforms.

See recent signals in this market

Strategic themes and signal pattern

Strategic Themes

Biologics CDMOBiosimilarsCell & Gene TherapymRNA ManufacturingPharmaceutical Supply Chain

Recent Signal Pattern

Most frequent signal typePartnership

Activity Trend (30d)

Rising

Prev 30dLast 30d

Sources tracked5

Total signals tracked3

Industry Peer Comparison

Ranked #5 of 10 peers by 30-day signal activity

Key Changes (30d)

PartnershipMar 18Verified

Samsung Biologics and Eli Lilly partner to establish a new Lilly Gateway Labs site in Korea to accelerate drug discovery and development.

Samsung Biologics Partners with Eli Lilly for New Gateway Labs in Korea

PartnershipMar 15Verified

This article discusses the potential impact of AI on the job market, referencing a report by Goldman Sachs.

Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs site in Korea

AcquisitionMar 12Verified

This article provides commentary on the semiconductor industry's trends and future outlook, without reporting on any specific new development or concrete event.

Samsung Biologics Acquires Maryland Biomanufacturing Facility from GSK for $280M

Signal history

3 total

AcquisitionOfficial sourceMar 12, 2026

This article provides commentary on the semiconductor industry's trends and future outlook, without reporting on any specific new development or concrete event.

Samsung Biologics Acquires Maryland Biomanufacturing Facility from GSK for $280M

Samsung Biologics will acquire a biologics manufacturing facility in Rockville, Maryland, from GSK for $280 million. This deal marks Samsung Biologics' first manufacturing presence in the U.S., adding 60,000 liters of drug substance capacity and retaining over 500 employees.

PartnershipOfficial sourceMar 10, 2026

Samsung Biologics and Eli Lilly partner to establish a new Lilly Gateway Labs site in Korea to accelerate drug discovery and development.

Samsung Biologics Partners with Eli Lilly for New Gateway Labs in Korea

Samsung Biologics has announced a collaboration agreement with Eli Lilly and Company to establish a Lilly Gateway Labs (LGL) site in Korea. This partnership aims to leverage Samsung Biologics' expertise to support Lilly's research and development initiatives within the region, potentially accelerating drug discovery and development processes.

PartnershipOfficial source—

This article discusses the potential impact of AI on the job market, referencing a report by Goldman Sachs.

Samsung Biologics Announces Collaboration with Lilly to Establish New Gateway Labs site in Korea

Samsung Biologics and Eli Lilly have entered a collaboration to establish a Lilly Gateway Labs site in Korea, aimed at supporting early-stage biotech companies. The new facility will be situated within Samsung Biologics' Bio Campus II and is scheduled for completion by July 2027.